Return to homepagePandemic Pact

to evaluate the potential efficacy of a Ribonucleic acid (RNA) vaccine against COVID-19

Grant number: INV-016635

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $1,080,771

  • Funder

    Gates Foundation

  • Principal Investigator

    N/A

  • Research Location

    United Kingdom

  • Lead Research Institution

    Imperial College London

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:42 minutes ago

View all publications at Europe PMC

Omicron breakthrough infections in vaccinated or previously infected hamsters.

A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.